Evidence map›Paper›PMID 42375349›Full record

ArticleFrontiers in immunology2026

Dominant T cell receptor clonotypes in adrenocorticotropic hormone-secreting pituitary carcinoma are the highest-frequency clones among CD4

Mariko Sugiyama, Shintaro Iwama, Kazuhito Takeuchi, Tomoko Kobayashi, Takanori Murase, Daisuke Hagiwara, Hao Chen, Yuichi Nagata, Ryuta Saito, Yoshiki Akatsuka and 1 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Mariko SugiyamaDepartment of Endocrinology and Diabetes, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Shintaro IwamaDepartment of Endocrinology and Diabetes, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Kazuhito TakeuchiDepartment of Neurosurgery, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Tomoko KobayashiDepartment of Endocrinology and Diabetes, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Takanori MuraseDepartment of Endocrinology and Diabetes, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Daisuke HagiwaraDepartment of Endocrinology and Diabetes, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Hao ChenDepartment of Immunology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Yuichi NagataDepartment of Neurosurgery, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Ryuta SaitoDepartment of Neurosurgery, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Yoshiki AkatsukaDepartment of Immunology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Hiroshi ArimaDepartment of Endocrinology and Diabetes, Nagoya University Graduate School of Medicine, Nagoya, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Context: Pituitary carcinoma is a rare and highly aggressive tumor. While anti-programmed cell death-1 (PD-1) therapy has shown efficacy in some cases, the factors that predict a favorable response remain largely unclear. Objective: To evaluate tumor-infiltrating lymphocytes (TILs) in pituitary carcinoma and to compare T-cell receptor (TCR) clonotypes between the pituitary and peripheral blood. Methods: A 34-year-old woman with Lynch syndrome and adrenocorticotropic hormone-secreting pituitary carcinoma with hepatic metastasis received anti-PD-1 therapy, achieving durable disease control exceeding 1 year. Immunohistochemistry was performed on treatment-naïve surgical tumor samples, and TCR repertoire analyses were conducted on both the tumor sample and peripheral blood mononuclear cells collected during effective anti-PD-1 therapy. Results: Treatment-naïve pituitary carcinoma tissues exhibited infiltration of CD4 Conclusions: The presence of CD4

Indexed as

ACTH-Secreting Pituitary AdenomaImmune Checkpoint InhibitorsLymphocytes, Tumor-InfiltratingPituitary NeoplasmsProgrammed Cell Death 1 ReceptorAdultCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesFemaleHumansLiver NeoplasmsReceptors, Antigen, T-CellImmune Checkpoint InhibitorsPDCD1 protein, humanProgrammed Cell Death 1 ReceptorReceptors, Antigen, T-CellCushing’s syndromeimmunotherapyPD-1pituitary cancerT−cell receptor repertoire

Identifiers

PMID42375349
PMCPMC13311078

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.